Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma

Authors: Seneviratne, JA, Ravindrarajah, D, Carter, DR, Zhai, V, Lalwani, A, Krishan, S, Balachandran, A, Ng, E, Pandher, R, Wong, M, Nero, TL, Wang, S, Norris, MD, Haber, M, Liu, T, Parker, MW, Cheung, BB, Marshall, GM

Source: Cancer Med
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)

Subject Terms: Indazoles, Pediatric Cancer, Pyridones, 32 Biomedical and Clinical Sciences, Cell Line, neuroblastoma, Neuroblastoma, Mice, Rare Diseases, anzsrc-for: 32 Biomedical and Clinical Sciences, Stem Cell Research - Nonembryonic - Human, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, Genetics, molecular biology, Humans, Animals, Enhancer of Zeste Homolog 2 Protein, Enzyme Inhibitors, RC254-282, Cancer, cancer biology, Cell Proliferation, Pediatric, anzsrc-for: 3211 Oncology and Carcinogenesis, Tumor, chromatin modifications and dynamics, epigenetics, Neurosciences, anzsrc-for: 1112 Oncology and Carcinogenesis, biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Drug Synergism, Histone-Lysine N-Methyltransferase, 3211 Oncology and Carcinogenesis, Stem Cell Research, Endoplasmic Reticulum Stress, Activating Transcription Factor 4, Xenograft Model Antitumor Assays, Orphan Drug, 5.1 Pharmaceuticals, anzsrc-for: 0601 Biochemistry and Cell Biology, Research Article

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/39501501
https://doaj.org/article/eb0bf02a0c794095a605600e20b3847f